Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neo-MASCT
- Development stage
- Phase 2
- Lead developer
- Sun Yat-sen University Cancer Center
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**Neo-MASCT** is an investigational, personalized autologous neoantigen-directed cellular immunotherapy that combines a neoantigen-loaded dendritic-cell vaccine with neoantigen-reactive autologous T cells. Dendritic cells are generated from a patient's peripheral blood, loaded with tumor neoantigens, and reinfused to prime tumor-specific immunity; antigen-pulsed dendritic cells are also used ex vivo to expand autologous cytotoxic T cells that are subsequently reinfused. The approach is intended to elicit and augment neoantigen-specific antitumor T-cell responses. It has been evaluated in a Phase I/II study in advanced non-small cell lung cancer and in a Phase II trial after radiofrequency ablation or surgical resection for primary hepatocellular carcinoma. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03205930))
- Other names
- Neo-MASCT
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on Neo-MASCT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neo-MASCT.